The Syndemics of HIV, Hepatitis, and Overdose

Similar documents
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis

CDC s Response to the Viral Hepatitis/Opioid Syndemic

Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations. Emily McCloskey USCA October 3, 2014

Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention

NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB. Prevention: NCHHSTP. Division of Viral Hepatitis

Targeted Outreach & Other Strategies for Increasing HCV Testing

Hepatitis B Virus and the Opioid Crisis

Hepatitis C in Massachusetts Epidemiology and Public Health Response

The HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)

Viral Hepatitis in the U.S.: Federal Partner Update

March XX, Washington, DC Washington, DC Washington, DC Washington, DC 20515

Presenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin

Viral Hepatitis. WHO Regional Office for Europe July 2013

Placing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in

Implementation of testing (and other interventions along the Continuum of Care)

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,

National Viral Hepatitis Action Plan Priority Populations Approach

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

ENDING THE EPIDEMICS: A NATIONAL, STATE, AND CITY APPROACH

Strategies to Address HCV

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

Stigma and HIV. Maria E. Alvarez, MPA. LEAD PUBLIC HEALTH ADVISOR Team Lead, Capacity Building Branch Partnerships Team

Opioid Overview Admiral Brett P. Giroir, M.D.

Integrating Hepatitis Services into HIV Programs: The Local Health Department Perspective

National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic

High Impact Prevention: Science, Practice, and the Future of HIV

FY2019 Labor, Health and Human Services, Education Appropriations Summary

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

HIV & HCV in TN: State of the State

Alabama s Emerging Hepatitis C Epidemic and Vulnerability to an Outbreak of HIV Infection Among Persons Who Inject Drugs

INTEGRATED HCV SCREENING AND TESTING IN SUBSTANCE ABUSE TREATMENT

Local Legislative Approval and Program Certification

Version for the Silent Procedure 29 April Agenda item January Hepatitis

Health Department Role: Eliminating HBV and HCV

CBA. Center of Excellence. Integration of Biomedical and Behavioral Interventions for HIV Prevention

Prevention and control of hepatitis B and C in the European Region of WHO

Update: ACIP Recommendations for Hepatitis B Vaccination

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2018 Appropriations

Overview of Evidence for Sterile Syringe Access. Hilary McQuie Western Director Harm Reduction Coalition

High Impact Prevention for People Who Inject Drugs. June 30, 2015

Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse

CDC s Efforts to End the Opioid Epidemic

Practical Solutions to Reduce Incidence of Liver Cancer. Nancy Steinfurth, Executive Director Liver Health Connection November 2017

Socioeconomic Factors

STD & HIV ANNUAL REPORT. An Annual Review of HIV and STD s reported in Oakland County, Michigan

Injury Chronic Disease Infant Mortality Maternal & Child Health Infectious Disease Life Expectancy

What is injection drug use?

The impact of economic recession on drug users and drug treatment

Just Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health

WHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections

Hepatitis A and B outbreaks in Massachusetts,

Interior AIDS Association

Opioid Use and Other Trends

Labor, Health and Human Services & Education Labor, Health and Human Services & Education

CHLAMYDIA, GONORRHEA & SYPHILIS: STDS ON THE RISE

Paying for Routine HIV Testing

Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago

Labor, Health and Human Services & Education Labor, Health and Human Services & Education

Global strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators

Monitoring the HCV care cascade to inform public health action

As a result of this training, participants will be able to:

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

DHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General , Hepatitis C Prevention and Control within Maryland

Infectious Diseases Florida Department of Health, HIV/AIDS Section/ Division of Disease Control and Health Protection Tallahassee, Florida

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Changing Course: statewide efforts to combat the opioid epidemic in California

JSNA Substance Misuse

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

5/2/2016. Dr Brooks has no relevant financial affiliations to disclose. (Update 04/15/16) Learning Objectives

Drug Use, Harm Reduction, and HIP

San Francisco Department of Public Health Program Collaboration and Service Integration Surveillance Baseline Assessment

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT

As a result of this training, participants will be able to:

Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,

Harm Reduction in Nigeria

The Faces of the Opioid Crisis

PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS

FY2019 Labor, Health and Human Services, Education Appropriations Summary

FY2018 Labor, Health and Human Services, Education Appropriations Summary

Planning for Action at the Local Level

Training Objectives. By the end of this session you will be able to: 2. Recognize key principles of harm reduction.

Addressing HIV among Hispanic/Latino MSM

*Public Health 101: Understanding the Importance of Public Health

Successful Prevention Strategies to Address the Opioid Crises

World Health Organization. A Sustainable Health Sector

HIV AND PEOPLE WHO INJECT DRUGS

CHLAMYDIA, GONORRHEA & SYPHILIS: STDS ON THE RISE

NationalHepatitisCPrevention Strategy

HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME

Save Lives and Save Money

Oregon s Syndemic: Substance Use, Overdose, STIs, associated conditions and IDU-related infections. Framework and Response Models

Children and AIDS Fourth Stocktaking Report 2009

ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES

Transcription:

The Syndemics of HIV, Hepatitis, and Overdose Sara Zeigler Associate Director for Policy Office of Policy, Planning and Partnerships (proposed) Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention USCA Hepatitis Pathway Session September 7, 2018 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director

Massive Increase in Opioid Deaths in United States Over 600,000 people have died from opioid overdose since 2000

Acute Hepatitis C Infections Continue to Soar and Progress Combatting Hepatitis B is Threatened Over 22,000 Americans die of viral hepatitis each year 45,000 Estimated Number of Cases 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 Hepatitis B Hepatitis C 0 YEAR Source: National Notifiable Diseases Surveillance System (NNDSS)

Increased Transmission of Viral Hepatitis to Infants Without preventive treatment, 40% of infants born to HBV-infected mothers will develop chronic infection Without treatment, a quarter will die from liver disease From 2009-2014, HCV infection among women giving birth nearly doubled MMWR, May 12, 2017; https://www.cdc.gov/hepatitis/hbv/perinatalxmtn.htm

Hepatitis A Outbreaks in Multiple States CDC has been assisting with multistate hepatitis A outbreaks Primarily among homeless persons, persons who use injection and noninjection drugs, and their close contacts More than 5,118 cases; 63 deaths Over 3,058 hospitalizations

Drug Overdoses and Hepatitis C: Interconnected Epidemics Drug Overdose Death Rates Reported New HCV Infections SOURCE: CDC/NCHS Data Visualization Gallery 2016 SOURCE: CDC National Notifiable Disease Surveillance System 2013-14

Annual HIV infections in the U.S. declined 15% from 2008-2015, then plateaued 50,000 45,000 40,000 45,200 15% One in 10 new HIV infections occur among people who inject drugs - - a decade of progress now threatened. 38,500 35,000 2008 2015 Prevented 34,000 cases at estimated cost savings for medical care of over $16 billion* Note. Estimates were derived from a CD4 depletion model using HIV surveillance data. *Farnham PG et al. Updates of Lifetime Costs of Care and Quality of Life Estimates for HIV-Infected Persons in the United States: Late Versus Early Diagnosis and Entry Into Care. JAIDS 2013; 64: 183-189. Estimates updated to 2017 dollars.

WHAT WORKS?

Comprehensive Community Action Works Mobilize multi-sector community action health care education agencies public health law enforcement Comprehensive syringe services programs (SSPs) stopping use of drugs prevent infections link patients to treatment do not increase drug use or crime MacArthur BMJ 2012. Aspinall E J et al. Int J. Epidemiology, 2014; Turner Addiction 2011; Hagan J Sub Abuse Treatment 2000; Sypsa JID 2017

Targeted Disease Prevention Strategies Respond quickly and comprehensively to Hepatitis A clusters Implement targeted vaccination strategy Ensure Hepatitis B vaccines and testing are reaching the people who need them Increase screening, diagnosis, and treatment of Hepatitis C and reduce barriers to treatment access Cost of treatment is decreasing 2014: $83,000 $153,000 2017: About $40,000

Rapid and Comprehensive Outbreak Response Makes All the Difference 233 people with HIV ~90% had hepatitis C co-infection 5% adults with HIV (population 3,143) Over $100 million in lifetime medical costs Comprehensive community based prevention services worked Essential partnerships with law enforcement, schools, healthcare, and others Continued focus on adherence to treatment Credit: Tyler Stewart / Associated Press

44 states and Puerto Rico have areas that are experiencing, or at risk for, increases or outbreaks of HCV/HIV CDC Resource: Managing HIV and hepatitis C outbreaks among persons who inject drugs - A guide for state and local health departments

$478,000: lifetime cost to treat someone with HIV infection For every $1 CDC spent on HIV testing, $2 were saved in direct medical costs $6.5 billion: estimated total healthcare costs associated with hepatitis C infection in 2011 The average cost of curing people with hepatitis C is not only cost-effective, but cost-saving to the healthcare system

Comprehensive action will reduce drug use, save money, and save lives. Prevention of Harmful Opioid Use Prevention of Viral Hepatitis and HIV Treatment of Substance Use Disorder Linkage to Care and Treatment